Nova Mentis News Today

DelveInsights, Fragile X Syndrome Pipeline Insight 2023 report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Fragile X Syndrome pipeline landscape. It covers the...

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing…

The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.

Wellbeing Digital Sciences Inc. , an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and... | April 18, 2023

Wellbeing Digital Sciences Inc. , an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and... | April 11, 2023

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global

KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder. According to a company press release, the results of a 10-person, open-label study will be used to support KGK’s client Nova Mentis’ drug development program under

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a No Objection letter...

Coronavirus Treatment and Cure news - updated 24/7/365. We link to the best sources from around the world. Get the latest news…